Roundtable discussion: Tadalafil study group

American Journal of Cardiology

Volumn 92, Issue 9 SUPPL. 1, 2003, Pages 58-65

  Kloner, Robert A ^a,b   Brindis, Ralph G ^c,d   Cheitlin, Melvin D ^d   Kuritzky, Louis ^e   Miller, Thomas A ^f   Padma Nathan, Harin ^a,g   Rosen, Raymond C ^h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

^c KAISER FOUNDATION HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^g The Male Clinic   (United States)

^h RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; NITRATE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SPIRONOLACTONE; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DEPRESSION; DOCTOR PATIENT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG UTILIZATION; ERECTILE DYSFUNCTION; HEADACHE; HEALTH CARE MANAGEMENT; HEART RATE; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MEDICAL SPECIALIST; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SPOUSE; TREATMENT CONTRAINDICATION;

EID: 0242663624     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00826-9     Document Type: Conference Paper

References (10)

1. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998;10:69-73; discussion 73-74 [see editorial comment].
2. DeBusk R, Drory Y, Goldstein I, Jackson G, Kaul S, Kimmel SE, Kostis JB, Kloner RA, Lakin M, Meston CM, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000;86:175-181.
3. Kloner R, Brown M, and the Sildenafil Study Group. Safety of sildenafil citrate in men with erectile dysfunction taking multiple antihypertensive agents [abstract]. Am J Hypertens 1999;12:37A.
4. Kloner R.A., Brown M., Prisant L.M., Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens. 14:2001;70-73.
5. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342:2000;145-153.
6. Drory Y., Shapira I., Fisman E.Z., Pines A. Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol. 75:1995;835-837.
7. Cheitlin M.D., Hutter A.M. Jr, Brindis R.G., Ganz P., Kaul S., Russell R.O. Jr, Zusman R.M. ACC/AHA expert consensus document use of sildenafil (Vi-agra) in patients with cardiovascular disease . J Am Coll Cardiol. 33:1999;273-282.
8. Shakir S.A.W., Wilton L.V., Boshier A., Layton D., Heeley E. Cardiovascular events in users of sildenafil results from first phase of prescription event monitoring in England . BMJ. 322:2001;651-652.
9. Muller J.E., Mittleman M.A., Maclure M., Sherwood J.B., Tofler G.H. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exercise. JAMA. 275:1996;1405-1409.
10. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients taking common antihypertensive therapies. Am J Cardiol 2003;92(9A):47M-57M.